Wilson L.D.CHIA-TI TSAI2020-12-302020-12-3020081547-5271https://www.scopus.com/inward/record.uri?eid=2-s2.0-39649117537&doi=10.1016%2fj.hrthm.2008.01.002&partnerID=40&md5=9a4af640d421f2c0b4f5facf62bac2dchttps://scholars.lib.ntu.edu.tw/handle/123456789/536557[SDGs]SDG32,4 thiazolidinedione derivative; angiotensin II; angiotensin receptor; angiotensin receptor antagonist; antiarrhythmic agent; candesartan; hydroxymethylglutaryl coenzyme A reductase inhibitor; peroxisome proliferator activated receptor gamma; peroxisome proliferator activated receptor gamma agonist; pioglitazone; congestive heart failure; disease association; disease exacerbation; drug effect; drug efficacy; drug mechanism; drug safety; editorial; heart atrium fibrillation; heart electrophysiology; heart failure; heart muscle conduction disturbance; heart muscle fibrosis; heart pacing; heart protection; hormone action; human; hypervolemia; mortality; nonhuman; pathophysiology; priority journal; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimidazoles; Blotting, Western; Disease Models, Animal; Electrophysiologic Techniques, Cardiac; Fibrosis; Heart Failure; Hypoglycemic Agents; Male; Rabbits; Tetrazoles; Thiazolidinedioneseditorial10.1016/j.hrthm.2008.01.002183136062-s2.0-39649117537